Skip to main content

Bipolar Disorders

What criteria differentiates between bipolar disorder with psychotic features and the bipolar type of schizoaffective disorder?
The US Food and Drug Administration (FDA) has accepted Alkermes’ New Drug Application (NDA) for ALKS 3831, a combination of olanzapine and samidorphan, the company announced.
An interactive voice application’s assessment of patient well-being through analysis of their speech was highly comparable with physicians’ tracking of patient well-being, according to a study published online in PLOS One.
Psych Congress Steering Committee member Vladimir Maletic, MD, MS, discusses how frequently patients can cycle between depression and mania.
Alkermes has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of the investigational drug ALKS 3831, a combination of the antipsychotic olanzapine and samidorphan, a novel molecular entity.
Back to Top